Kornimate/medical-research-clean huggingface dataset:
an international registry of the wingspan™ stent system for the treatment of intracranial atherosclerotic stenosis

Conditions: Intracranial Atherosclerosis

Summary: the iriss study is designed to collect clinical and angiographic outcomes data when stenting intracranial atherosclerotic lesions using the wingspan™ stent system with gateway™ pta balloon catheter in routine clinical practice.

the wingspan™ stent system and gateway™ pta balloon catheter have ce mark and are commonly used in europe. all the data collected in this registry will be from patients treated according to the physician's choice, per instructions for use, per approved indications and per local standard of care. the results from this registry will provide an understanding of the use and outcomes associated with the wingspan™ stent in a real world setting.

Eligibility criteria:
inclusion criteria: * symptomatic stenosis of one of those intracranial arteries: internal carotid artery (ica ), m1 segment of the mca, v4 segment of vertebral artery, basilar artery * a modified rankin score of ≤ 3 * a target vessel diameter between 2mm and ≤ 4.5mm * length of the target lesion of ≤ 14 mm * patient older than 40 years old exclusion criteria: * patient previously stented at the target lesion * intracranial stenosis related to disease such as: arterial dissection, moya moya disease, vasculitis, radiation induced vasculopathy or fibromuscular dysplasia * complete occlusion of the artery on the imaging assessment * contraindications to antithrombotic and/or anticoagulant therapies * women who are pregnant or breast-feeding * patient not likely to be available for follow-up * patient protected by the law (safeguard of justice, supervision or trusteeship)

Keywords: intracranial atherosclerosis stenosis icad atherosclerotic lesions stenting
correlation between electromyography and thickness change of the trunk muscles in subjects with low back pain

Conditions: Low Back Pain

Summary: transversus abdominis (tra) and lumbar multifidus (lm) muscle have been proposed to play key role in stability of the lumbosacral spine. the muscles' functional and/or structural deficits have been linked to the low back pain (lbp) syndrome. evaluation of the transversus abdominis and lumbar multifidus muscles' function in clinical practice is scarce and not well defined due to number of reasons. surface electromyography of tra and lm muscles, as a method of examining muscles function, is not involved in clinical routine. rehabilitative ultrasound imaging (rusi) of the tra and lm, apart from providing information about their morphology, could be helpful in assessing their function. since concentric muscle contraction results in the shortening and thickening of the muscle, evaluation of the potential association between muscle's morphometry, assessed by the ultrasound, and electromyography, may be of potential clinical interest. however, this potential relationship is context-dependant. our aim was to establish the difference in the thickness change of the tra and lm muscle during activation in subjects with and without low back pain, and to establish the possible correlation between electromyography and the thickness change of these muscles assessed by ultrasound in both groups of subjects.


Eligibility criteria:
inclusion criteria: low back pain, with or without radiculopathy, that lasted for at least 12 weeks, caused by prolapsed intervertebral disc (pid), confirmed by magnetic resonance imaging (mri) exclusion criteria: the exclusion criteria for all participants were pregnancy,diabetes mellitus,corticosteroids administrated in one months or less prior to enrollment, spinal fractures, surgery, infectious diseases, tumors, spina bifida, advanced forms of spinal deformity, hip diseases, and neuromuscular disorders. additional exclusion criteria for lbp participants were self-reported pain levels of less than 3 on the visual analog scale to account for patients commonly encountered in clinical practice, and inability to remain in prone and supine hook-lying positions for 10 minutes each in order to ensure compliance.
safety, biomarker study of rl-007 in subjects with schizophrenia

Conditions: Cognitive Impairment; Schizophrenia

Summary: the purpose of this study is to assess the safety and effects on electrical activity in the brain of an investigational drug (rl-007) for improving cognition in patients with schizophrenia

potential participants will first be given an informed consent document and have the study explained to them. all patients who provide written informed consent will undergo screening to determine eligibility for the study. patients who meet all eligibility criteria will be admitted to the clinic for 5 days / 4 nights as an in-patient. during this time, participants will be assigned to a specific dose cohort and will receive sequence that includes both placebo and rl-007. brain activity and cognitive performance will be assessed on study days 2 and 4.

Eligibility criteria:
key inclusion criteria: * provide a written informed consent * diagnosis of schizophrenia, as defined by dsm-5 and evaluated with the mini plus interview * positive and negative symptoms severity score (panss) of 40 - 80 (inclusive), and a score of 4 or less on the following panss items: p2, p3, p5, p6, g6. * currently being treated with a single protocol-allowed antipsychotic at a stable dose and clinically stable for at least 8 weeks before admission (note: allowed meds = aripiprazole, brexipiprazole, paliperidone, risperidone) * modified simpson-angus scale total score \<= 4 * at least 1 standard deviation below normative value of total number of words recalled on the hopkins verbal learning test * bmi \<= 38 key exclusion criteria: * history of hospitalization for medical indication within 4 weeks prior to screening or psychiatric hospitalization within 3 months prior to screening * use of any other psychoactive medication known to interfere with the eeg/erp assessments within 1 week prior to screening or during the study period. * subjects who present a serious risk of suicide * any history of gi surgery, or other condition, that may affect gi absorption or any history of gi bleeding or peptic ulcer. * evidence or history of significant cognitive impairment, other than associated with schizophrenia, that in the judgement of the investigator would confound secondary or exploratory assessments or prevent safe and satisfactory completion of the study protocol. * moderate to severe alcohol use disorder, per dsm-5 within 3 months of admission visit. * positive alcohol breath test or urine test for drugs of abuse at either screening or admission visit. * currently smoking more than 1 pack of cigarettes a day and unable or unwilling to maintain smoking to less than 1 pack a day during in-patient portion of study. * positive test result for sars-cov2 prior to admission per site standards. * positive test for hepatitis b, hepatitis c or hiv * subjects whose hair type or style is likely to interfere with successful application of scalp electrodes. * subjects with needle phobia or in whom venous access is technically difficult. * other unspecified reasons that, in the opinion of the pi or sponsor, make the subject unsuitable for enrollment.
a study to assess the safety and efficacy of adalimumab when added to inadequate standard anti-rheumatic therapy in patients with active rheumatoid arthritis

Conditions: Rheumatoid Arthritis

Summary: this is an open-label, multi-center study in which adalimumab (d2e7) is administered subcutaneously 40 mg every other week in addition to current anti-rheumatic therapies. patients must have active disease despite standard anti-rheumatic therapy.


Eligibility criteria:
inclusion criteria: * subjects must be 18 years or older * acr criteria for diagnosis of ra for at least 3 months. * active ra as defined by das28 \>= 3.2 at study entry. * unsatisfactory response or intolerance to prior dmards. * a negative pregnancy test (serum hcg) for women of childbearing potential prior to start of study treatment. * use of reliable method of contraception e.g. iuds, condoms, or hormone (oral, implantable, or injectable) contraceptives by all female patients of childbearing potential. male patients with procreative capacity should also ensure that effective contraception is used during the study and for 70 days after study completion exclusion criteria: * prior treatment with alkylating agents such as cyclophosphamide or chlorambucil. * prior treatment with intravenous immunoglobulin or any investigational agent within 30 days, or 5 half lives of the product, whichever is longer. * prior treatment with investigational biologic therapy (e.g. anti cd4) * treatment within the last 2 months with approved biologic therapy (eg etanercept, infliximab, anakinra) * prior treatment with total lymphoid irradiation * history of cancer or lymphoproliferative disease other than a successfully and completely treated squamous cell or basal cell carcinoma. * history of or current acute inflammatory joint disease of origin other than ra, e.g. mixed connective tissue disease, systemic lupus erythematosus etc. * history of uncontrolled diabetes, unstable ischemic heart disease, active inflammatory bowel disease, active peptic ulcer disease, recent stroke (within 3 months) and any other condition which, in the opinion of the investigator, would put the subject at risk by participation in the protocol. * positive serology for hepatitis b or c indicating active infection * history of positive hiv status. * persistent infection, or severe infections requiring hospitalization or treatment with iv antibiotics within 30 days, or oral antibiotics within 14 days prior to enrollment. * female subjects who are pregnant or breast-feeding. * history of clinically significant drug or alcohol abuse in the last year. * previous diagnosis or signs of demyelinating diseases * history of active tuberculosis (tb), histoplasmosis or listeriosis. * signs of previous tb infection (chest x-ray signs or positive ppd skin test). the diagnosis of previous tb infection will be based on chest x-ray signs and on ppd skin test.
anodal transcranial direct current stimulation (tdcs) in the treatment of tobacco addiction

Conditions: Addiction; Smoking

Summary: the aim of this study is to determine whether a powerful technique of noninvasive brain stimulation, transcranial direct current stimulation (tdcs), could reduce cigarette smoking and constitute a treatment of tobacco addiction.

tobacco is estimated to cause more than 5 millions yearly deaths in the developed world. although most smokers would like to quit, relapse rates remain high. it seems that this relapse is linked with the process of craving, which is a powerful desire to smoke elicited by smoking deprivation or exposure to situations or cues that are associated with smoking. neuroimaging studies have shown that the dorsolateral prefrontal cortex (dlpfc), and especially the right part, is critically involved in processing the craving of smoking. increasing the activity of the dlpfc by noninvasive brain stimulation has been demonstrated to be effective in decreasing craving symptoms in cigarette smokers. the aim of this study is to determine whether a powerful technique of noninvasive brain stimulation, transcranial direct current stimulation (tdcs), could reduce cigarette smoking. tdcs is a painless and safe brain stimulation method capable of modulating cortical excitability. the nature of these modulations depends on stimulation polarity: anodal tdcs is thought to cause neuronal depolarisation and thus enhancing cortical excitability whereas cathodal stimulation is proposed to reduce excitability. the investigators hypothesize that anodal tdcs applied repetitively to the right dlpfc could constitute a treatment of tobacco addiction. therefore, the investigators will conduct a sham-tdcs-controlled, randomized, double-blind study.

Eligibility criteria:
inclusion criteria: * age from 18 to 55 years old * tobacco consumption from 10 to 25 cigarettes, for at least 1 year * strong tobacco dependence at the fagerstrom test (score \>= 5) * motivation to quit with a score \>=12 at the motivation to quit smoking scale (q-mat) * informed consent exclusion criteria: * concomitant axe i psychiatric disorder according to the diagnostic and statistical manual of mental disorders, 4th edition (dsm iv) * other addictive disorder (dsm iv) * no history of smoking cessation drug the previous year * psychotropic treatment * pregnancy or nursing

Keywords: tobacco smoking tdcs dlpfc
impact on french physician's haemophilia treatment management decision based on systematic joint examination

Conditions: Hemophilia A

Summary: this low interventional study aims to describe if and how the haemophilia treatment management decisions are impacted by a systematic joint examination (ultrasound, functional, physical) in patients with haemophilia a in france.

the study will assess the behavior of the physicians with regards to haemophilia management decisions, and if systematic joint examination have an impact on their decisions. the main objective is to evaluate if the use of head-us and haemophilia joint health score (hjhs) have an impact on these decisions. the study is classified as a low-interventional study due to mandated systematically assessment (head-us, hjhs) on patients which may not be part of routine clinical practice.

Eligibility criteria:
inclusion criteria: * age 6-40 years * haemophilia a patients treated with plasma-derived factor viii (pdfviii) or recombinant (conventional or extended half-life) factor viii (rfviii) * at least one joint bleeding episode prior to inclusion * signed informed consent exclusion criteria: * enrolment in another concurrent clinical interventional study, or intake of an investigational medicinal product, within three months prior to inclusion in the study * presence of factor viii antibodies (inhibitors) (≥0.60 bethesda unit \[bu\]/ml) at the latest available inhibitor test * joint surgery over the past year prior to inclusion in one of the following joints; left knee, right knee, left elbow, right elbow, left ankle and right ankle * more than one joint replacement

Keywords: joint health
evaluation of the effects of rehabilitation using the "wii" on upper limb kinematics in chronic stroke patients.

Conditions: Post-stroke Hemiparetic Patients (at Least 6 Months Post Stroke); Age Between 18-75 Years

Summary: the purpose of this study is to evaluate changes in strategies of hemiparetic upper limb movement in chronic stroke patients following rehabilitation using the "nintendo wii". the investigators hypothesize that patients will increase their use of compensatory strategies following this rehabilitation.

the principal aim of this study is to evaluate changes in strategies of hemiparetic upper limb movement in chronic stroke patients following twelve one hour sessions of rehabilitation using the "nintendo wii" over a period of four weeks, and to compare with a group of patients receiving traditional upper limb rehabilitation of the same duration. the investigators hypothesize that the use of compensatory strategies will increase in the group receiving the "wii" rehabilitation while they will decrease in the group receiving traditional rehabilitation. the investigators further hypothesize that this will have an impact on the functional benefit with a greater improvement of function in the group receiving traditional rehabilitation.

Eligibility criteria:
inclusion criteria: age 18 to 75 years right handed hemiparesis following vascular lesions of a single hemisphere of more than 6 months duration. not a regular 'wii' user able to bring the hand to the mouth. no botulinum toxin injections within the previous 3 months having given informed consent exclusion criteria: major cognitive or perceptive deficits cerebellar syndrome epileptic fits within the previous year pacemaker user un-corrected visual deficits no social security

Keywords: hemiparesis, rehabilitation, wii, upper limb, movement strategies.
early assessment of treatment response using functional diffusion mapping

Conditions: Prostate Cancer

Summary: this study will evaluate the feasibility of identifying changes in diffusion mri characteristics of bone that correlates with response to therapy in men with metastatic prostate cancer.

this study will evaluate a special type of mri (magnetic resonance imaging) scan that measures the movement of water molecules through tissue called diffusion mri. researchers are using this new mri technology to track the diffusion, or movement, of water through tumor tissue, and map these changes as a cancer patient undergoes treatment. early research seems to indicate that tumor cells restrict the movement of water, so as tumor cells die, the movement of water changes within the tumor. these changes in the movement (diffusion) of water may help doctors determine earlier than traditional tests whether a patient's cancer is responding (getting better) to treatment. this study will evaluate the feasibility of identifying changes in diffusion mri characteristics of bone that correlates with response to therapy in men with metastatic prostate cancer.

Eligibility criteria:
inclusion criteria: * diagnosis of prostate cancer. * evidence of metastatic disease by bone scan. * patients must be initiating systemic therapy for metastatic disease. * new d2 disease beginning therapy with androgen deprivation. * crpc (castration resistant prostate cancer) beginning systemic non hormonal therapy. * patients must be willing to provide the blood samples for the correlative markers. * patients must be able to lie flat in an mri (magnetic resonance imaging) magnet for 30-60 minutes. * life expectancy of 12 weeks or greater. * all patients must be informed of the investigational nature of this study and must sign an informed consent in accordance with institutional and federal guidelines. exclusion criteria: * contraindication to mri imaging. * patients who require sedation with general anesthesia to undergo mri imaging. * weight greater than 275 pounds.
eurosida as an external comparator to motivate trials

Conditions: HIV; AIDS

Summary: human immunodeficiency virus (hiv) infected patients who meet the entry criteria for the maraviroc pivotal trials (maraviroc versus optimized therapy in viremic antiretroviral treatment-experienced patients, motivate) will be identified from the eurosida hiv cohort. the rates of specific clinical adverse events in this identified patient population will be compared with the rates of these events in the participants of the motivate trials.

all patients in eurosida cohort that meet the entry criteria of motivate trials are included without any sampling.

Eligibility criteria:
inclusion criteria: * patient aged over 16 at baseline. * viral load (vl) \> 5000 copies/ml at baseline (and measured in 6 months prior to baseline). * no changes in antiretroviral (arv) regimens in the month period prior to baseline, or on no arvs in the month prior to baseline. * \> 3 months exposure (sequential or cumulative) to at least 3 of the following; * any nucleoside or nucleotide reverse transcriptase inhibitor (nrti) * non-nucleoside reverse transcriptase inhibitor (nnnrti) * protease inhibitor (pi ) * enfuvirtide exclusion criteria: none
covid-19 and vitamin d: length of hospital stay and mortality

Conditions: COVID-19 Pandemic; Vitamin D Deficiency

Summary: the lack of a pharmacological treatment in the covid-19 pandemic has pushed scientists to search for this issue. maintaining optimal health is parallel to adequate and balanced nutrition. in this context, can the protective properties of vitamin d play an important role in this pandemic? brought with it the thought. in this study, it was aimed to examine the effect of vitamin d on mortality and hospital stay in covid-19 disease.

this research was conducted to examine the effect of vitamin d on mortality and hospital stay in covid-19 disease. for this, the approval of the ministry of health and then the ethics committee was obtained. for this reason, patients with positive pcr tests and hospitalized patients with vitamin d levels in their biochemistry were included in the study. the data of the patients were obtained from the medical records. information such as age, gender, comorbidities, length of hospital stay, vitamin d level were included in the study. according to the statistical analyzes obtained from these data, it has been shown that vitamin d level has no effect on mortality and hospital stay in covid-19 disease.

Eligibility criteria:
inclusion criteria: * covid-19 pcr (polymerase chain reaction) test positive * vitamin d level in biochemical parameters * adult patients hospitalized for covid-19 exclusion criteria: -patients using drugs that may affect vitamin d absorption, such as corticosteroids, cholesterol-lowering agents, phenobarbital and phenytoin-containing agents

Keywords: covid-19 vitamin d length of stay mortality
dynamics in bone turnover markers during and after short-term glucocorticoid treatment in patients with an inflammatory joint disease

Conditions: Osteoporosis; Osteoporosis, Steroid Induced; Inflammatory Rheumatism

Summary: bone turnover markers (btms) are recommended as an important tool in follow-up of osteoporosis treatment. however, there is a lack of knowledge in the reliability of btms during and after glucocorticoid treatment. glucocorticoids suppresses btms during treatment with at least 30% and, moreover, glucocorticoids increase the risk of fractures. patients with an inflammatory joint disease are at increased risk of osteoporosis, and disease flares are often treated with glucocorticoids, which in turn can lead to loss in reliability of the btms in patients who also are on osteoporosis treatment. there is a need of more knowledge on btm changes during and after glucocorticoid treatment for optimized patientcare, reduced risk of side effects and reduced health economic costs.


Eligibility criteria:
inclusion criteria: * diagnosis of inflammatory rheumatic joint disease * indication of disease modifying treatment initiation with or without glucocorticoids or * stable dmard treatment with parenteral glucocorticoid injection exclusion criteria: * known osteoporosis or osteoporosis treatment * women during the transitory phase * oestrogen treatment * any fracture within the last year * chronic glucocorticoid treatment * glucocorticoid treatment within the last year prior to inclusion * active cancer * kidney failure

Keywords: bone turnover bone turnover markers glucocorticoids